Veludacigib
Term · Oncology and biomedicine · MLC-T-ONC-017487
An orally bioavailable inhibitor of diacylglycerol kinase zeta (DGKzeta), with potential antineoplastic activity. Upon oral administration, veludacigib inhibits the activity of DGKzeta. This prevents the phosphorylation of diacylglycerol (DAG) to phosphatidic acid (PA), and modulates the DAGzeta-regulated cellular signaling pathways. This may inhibit the proliferation of tumor cells in which DGKzeta is overactivated. DGKzeta is overexpressed in certain cancer cells and plays an important role in tumor cell survival. DAGzeta may also play a key role in tumor immunosuppression.
| Identifier | MLC-T-ONC-017487 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | DGKzeta inhibitor BAY2965501; DGKZ inhibitor BAY2965501; DGKzi BAY2965501; diacylglycerol kinase zeta inhibitor BAY2965501 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-017487",
"term": "Veludacigib",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable inhibitor of diacylglycerol kinase zeta (DGKzeta), with potential antineoplastic activity. Upon oral administration, veludacigib inhibits the activity of DGKzeta. This prevents the phosphorylation of diacylglycerol (DAG) to phosphatidic acid (PA), and modulates the DAGzeta-regulated cellular signaling pathways. This may inhibit the proliferation of tumor cells in which DGKzeta is overactivated. DGKzeta is overexpressed in certain cancer cells and plays an important role in tumor cell survival. DAGzeta may also play a key role in tumor immunosuppression.",
"synonyms": [
"DGKzeta inhibitor BAY2965501",
"DGKZ inhibitor BAY2965501",
"DGKzi BAY2965501",
"diacylglycerol kinase zeta inhibitor BAY2965501"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/veludacigib/"
}
Record 17,180 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.